News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes


7/15/2013 9:47:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company, will present clinical data in a poster session on Wednesday, July 17, 11:45 a.m.—2:15 p.m. EDT, at the Alzheimer’s Association International Conference (AAIC) that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial. By detecting a specific fluorescent signature of ligand-marked beta amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a 200% differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer’s disease.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES